Compare Eli Lilly And Co (LLY) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs NICE Ltd — how do they compare? Eli Lilly And Co trades at $1,173.56 (market cap $1.04T), while NICE Ltd trades at $116.73 (market cap $6.81B). The key difference: Eli Lilly And Co is far larger — about 152.7× NICE Ltd's market cap, and Eli Lilly And Co pays a 0.59% dividend while NICE Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and NICE Ltd for 15 Days on average.
| LLY | NICE | |
|---|---|---|
Market Cap | $1.04T | $6.81B |
Volume | 3,064,878 | 382,395 |
Sector | Health | Technology |
52-Week High | $1.28K | $137.68 |
52-Week Low | $799.57 | $83.15 |
Typical Hold Time | 93 Days | 15 Days |
Enterprise Value | $1.09T | $6.54B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
NICE trades at $116.83, up 0.35% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.70 actual versus $2.63 expected, and was recently named a leader in the IDC MarketScape for contact center platforms (Business Wire, 2026-10-01). Revenue for 2025 was $2.95 billion with a net income margin of 20.78%.
The outlook is positive, supported by AI-driven growth and a reasonable valuation with a P/E of 17.08. However, risks include margin compression from increased investment and potential market volatility. Analyst sentiment is bullish with 12 buy ratings and no sells, but investors should monitor execution on AI initiatives and competitive pressures in the CX software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
